Silk Road Medical (FRA:2OW) Buyback Yield % : -1.32 (As of Sep. 22, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Silk Road Medical Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Silk Road Medical's current buyback yield was -1.32%.

Silk Road Medical Buyback Yield % Historical Data

The historical data trend for Silk Road Medical's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silk Road Medical Buyback Yield % Chart

Silk Road Medical Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

Get a 7-Day Free Trial

-9.00

-3.72

-0.46

-5.70

-0.83

Silk Road Medical Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Buyback Yield %	Get a 7-Day Free Trial															-0.51	-0.09	-0.90	-	-4.82

Competitive Comparison of Silk Road Medical's Buyback Yield %

For the Medical Devices subindustry, Silk Road Medical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silk Road Medical's Buyback Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Silk Road Medical's Buyback Yield % falls into.

Silk Road Medical Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Silk Road Medical's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	3.564)	/	430.8205
	=	-0.83%

Silk Road Medical's annualized Buyback Yield for the quarter that ended in Jun. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	12.139)	*	4	/	1007.19
	=	-4.82%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Jun. 2024) data.

Silk Road Medical Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Silk Road Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (FRA:2OW) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

SILK:USA

Address

1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089

Website

https://www.silkroadmed.com

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.

Silk Road Medical Headlines

No Headlines